[{"internal_id": 68566856, "Award ID": "U24EY029904", "Award Amount": 7664347.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-17", "CFDA Number": "93.867", "Description": "NOVEL MODEL SYSTEMS FOR THE STUDY OF CONE DISORDERS AND OTHER HERITABLE RETINAL DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "TX", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ddcd398f-5e59-e840-2368-a57b84efdc7d-C", "generated_internal_id": "ASST_NON_U24EY029904_7529"}, {"internal_id": 68566075, "Award ID": "U24EY029890", "Award Amount": 7261894.0, "Award Type": "COOPERATIVE AGREEMENT (B)", "Base Obligation Date": "2018-09-17", "CFDA Number": "93.867", "Description": "RETINAL DISEASE MODELS FOR TRANSLATIONAL PHOTORECEPTOR REPLACEMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "PA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "b655b3eb-6e27-dfdd-c16c-ad7f8949f987-C", "generated_internal_id": "ASST_NON_U24EY029890_7529"}, {"internal_id": 65894746, "Award ID": "R25EY029127", "Award Amount": 760790.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-04-26", "CFDA Number": "93.310", "Description": "VIRTUAL REALITY AUGMENTED HANDS-ON CRYO-EM TRAINING", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "3d0e924f-2881-5f66-8511-7122b17340d9-C", "generated_internal_id": "ASST_NON_R25EY029127_7529"}, {"internal_id": 49769280, "Award ID": "R01NS102432", "Award Amount": 3006146.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2017-08-14", "CFDA Number": "93.853", "Description": "AIBP AND REGULATION OF NEUROPATHIC PAIN", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "ce42d274-7283-659b-de1c-e11666794c48-C", "generated_internal_id": "ASST_NON_R01NS102432_7529"}, {"internal_id": 94714069, "Award ID": "R01EY031248", "Award Amount": 1650899.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-23", "CFDA Number": "93.867", "Description": "NOVEL MECHANISM CONTROLLING CALCIUM SIGNALING TO TREAT AND PREVENT NEURODEGENERATION IN EARLY STAGE GLAUCOMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "466bb7e5-0742-3fc2-5029-530901df9261-C", "generated_internal_id": "ASST_NON_R01EY031248_7529"}, {"internal_id": 94714471, "Award ID": "R01EY030847", "Award Amount": 1621252.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2020-01-31", "CFDA Number": "93.867", "Description": "INDUCTION OF RETINAL DEVELOPMENT BY THE PERIPODIAL EPITHELIUM IN DROSOPHILA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "IN", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "74ccc06e-57e8-7489-fbc7-f6229ad4aaf6-C", "generated_internal_id": "ASST_NON_R01EY030847_7529"}, {"internal_id": 85588285, "Award ID": "R01EY030747", "Award Amount": 1596066.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-09-13", "CFDA Number": "93.867", "Description": "ALZHEIMER'S DISEASE ADMINISTRATIVE SUPPLEMENT FOR NIH GRANT NOVEL MECHANISM CONTROLLING CALCIUM SIGNALING TO TREAT AND PREVENT NEURODEGENERATION IN EARLY STAGE GLAUCOMA", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "466bb7e5-0742-3fc2-5029-530901df9261-C", "generated_internal_id": "ASST_NON_R01EY030747_7529"}, {"internal_id": 80401655, "Award ID": "R01EY030081", "Award Amount": 2365077.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2019-04-22", "CFDA Number": "93.867", "Description": "SUSTAINED DELIVERY OF THERAPEUTICS TO THE VISUAL SYSTEM USING GENETICALLY MODIFIED AUTOLOGOUS MESENCHYMAL STEM CELLS TO TREAT BLINDING DISEASES", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_R01EY030081_7529"}, {"internal_id": 67833544, "Award ID": "R01EY028027", "Award Amount": 2156028.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-08-16", "CFDA Number": "93.867", "Description": "ANTIGEN-INDEPENDENT SUPPRESSION OF OCULAR ANGIOGENESIS VIA THE FC RECEPTOR", "Place of Performance Country Code": "USA", "Place of Performance State Code": "VA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "d604415e-e1c8-650f-1b30-5e424b71fcf7-C", "generated_internal_id": "ASST_NON_R01EY028027_7529"}, {"internal_id": 49740246, "Award ID": "R01EY026291", "Award Amount": 2084926.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2016-07-07", "CFDA Number": "93.867", "Description": "CIRCADIAN REGULATION OF RPE FUNCTIONS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "67975889-0c6e-1397-5358-e9abc4723360-C", "generated_internal_id": "ASST_NON_R01EY026291_7529"}, {"internal_id": 49740026, "Award ID": "R01EY024590", "Award Amount": 2992615.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2014-08-14", "CFDA Number": "93.867", "Description": "IDENTIFICATION OF OPTIMUM SPECTACLE PRESCRIPTIONS FOR PATIENTS WITH DOWN SYNDROME", "Place of Performance Country Code": "USA", "Place of Performance State Code": "OH", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "18478032-6084-4969-2e94-0f121ba8b8b2-C", "generated_internal_id": "ASST_NON_R01EY024590_7529"}, {"internal_id": 49739867, "Award ID": "R01EY023219", "Award Amount": 4475902.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2013-05-01", "CFDA Number": "93.867", "Description": "METASTABLE CRYSTALLINS: STRUCTURE AND STABILIZATION", "Place of Performance Country Code": "USA", "Place of Performance State Code": "MO", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f261384c-3ac1-b344-de46-81708f87aa6a-C", "generated_internal_id": "ASST_NON_R01EY023219_7529"}, {"internal_id": 49739593, "Award ID": "R01EY021205", "Award Amount": 5375933.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2011-02-22", "CFDA Number": "93.310", "Description": "CHARACTERIZATION OF PURIFIED MYOCILIN: GLAUCOMA AS A PROTEIN MISFOLDING DISEASE", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "f7c481d7-071a-ead9-3bda-e4e7d1e903a7-C", "generated_internal_id": "ASST_NON_R01EY021205_7529"}, {"internal_id": 49739029, "Award ID": "R01EY016435", "Award Amount": 4445917.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-12-16", "CFDA Number": "93.867", "Description": "RETINAL MECHANISMS OF REFRACTIVE DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "GA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "4d4ce585-e95e-2593-758c-86dc120820ad-C", "generated_internal_id": "ASST_NON_R01EY016435_7529"}, {"internal_id": 49738960, "Award ID": "R01EY015788", "Award Amount": 5185830.68, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2007-06-05", "CFDA Number": "93.867", "Description": "MECHANISMS OF VISUAL MAP DEVELOPMENT", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CT", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "1882697f-2df0-529a-ed60-116702c184a7-C", "generated_internal_id": "ASST_NON_R01EY015788_7529"}, {"internal_id": 49738638, "Award ID": "R01EY011996", "Award Amount": 7557620.32, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2008-08-27", "CFDA Number": "93.867", "Description": "RETINAL DISEASE: MOLECULAR BASIS AND PATHOPHYSIOLOGY", "Place of Performance Country Code": "USA", "Place of Performance State Code": "ME", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "023bc6ff-e791-fc8c-47cb-ebca0c5a7fa7-C", "generated_internal_id": "ASST_NON_R01EY011996_7529"}, {"internal_id": 69726117, "Award ID": "R00EY026994", "Award Amount": 752296.0, "Award Type": "PROJECT GRANT (B)", "Base Obligation Date": "2018-09-21", "CFDA Number": "93.867", "Description": "COORDINATION OF EYE AND HEAD MOVEMENTS IN CENTRAL FIELD LOSS", "Place of Performance Country Code": "USA", "Place of Performance State Code": "CA", "COVID-19 Obligations": null, "Infrastructure Obligations": null, "recipient_id": "fe69ad55-4387-8038-bd59-4fcf87271051-C", "generated_internal_id": "ASST_NON_R00EY026994_7529"}]